Homotypic RANK signaling differentially regulates proliferation, motility and cell survival in osteosarcoma and mammary epithelial cells

Journal of Cell Science

Volumn 125, Issue 4, 2012, Pages 943-955

  Beristain, Alexander G ^a   Narala, Swami R ^a   Di Grappa, Marco A ^a   Khokha, Rama ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

Autocrine; Cancer; RANKL

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B;

ANCHORAGE INDEPENDENT GROWTH; ANIMAL CELL; ARTICLE; BREAST EPITHELIUM; CARCINOGENICITY; CELL INVASION; CELL MOTILITY; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; INTRACELLULAR SIGNALING; MOUSE; NONHUMAN; OSTEOBLAST; OSTEOSARCOMA CELL; PRIORITY JOURNAL;

ANIMALS; AUTOCRINE COMMUNICATION; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; CELL TRANSFORMATION, NEOPLASTIC; CONTACT INHIBITION; EPITHELIAL CELLS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; MAMMARY GLANDS, ANIMAL; MESODERM; MICE; NEOPLASM INVASIVENESS; OSTEOBLASTS; OSTEOSARCOMA; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; SIGNAL TRANSDUCTION;

EID: 84861213409     PISSN: 00219533     EISSN: 14779137     Source Type: Journal    
DOI: 10.1242/jcs.094029     Document Type: Article

References (57)

1. Akiyama, T., Choong, P. F. M. and Dass, C. R. (2010). RANK-Fc inhibits malignancy via inhibiting ERK activation and evoking caspase-3-mediated anoikis in human osteosarcoma cells. Clin. Exp. Metastasis 27, 207-215.
2. Anderson, D. M., Maraskovsky, E., Billingsley, W. L., Dougall, W. C., Tometsko, M. E., Roux, E. R., Teepe, M. C., DuBose, R. F., Cosman, D. and Galibert, L. (1997). A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 390, 175-179.
3. Armstrong, A. P., Miller, R. E., Jones, J. C., Zhang, J., Keller, E. T. and Dougall, W. C. (2008). RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes. Prostate 68, 92-104.
4. Bao, W. and Strömblad, S. (2004). Integrin alphav-mediated inactivation of p53 controls a MEK1-dependent melanoma cell survival pathway in three-dimensional collagen. J. Cell Biol. 167, 745-756.
5. Beristain, A. G., Zhu, H. and Leung, P. C. (2011). Regulated expression of ADAMTS- 12 in human trophoblastic cells: a role for ADAMTS-12 in epithelial cell invasion? PLoS ONE 6, e8473.
6. Boyce, B. F. and Xing, L. (2007). Biology of RANK, RANKL, and osteoprotegerin. Arthritis Res. Ther. 9 Suppl. 1, S1
7. Bucay, N., Sarosi, I., Dunstan, C. R., Morony, S., Tarpley, J., Capparelli, C., Scully, S., Tan, H. L., Xu, W., Lacey, D. L. et al. (1998). osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev. 12, 1260-1268.
8. Canon, J. R., Roudier, M., Bryant, R., Morony, S., Stolina, M., Kostenuik, P. J. and Dougall, W. C. (2008). Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis. Clin. Exp. Metastasis 25, 119-129.
9. Cao, Y., Bonizzi, G., Seagroves, T. N., Greten, F. R., Johnson, R., Schmidt, E. V. and Karin, M. (2001). IKKalpha provides an essential link between RANK signaling and cyclin D1 expression during mammary gland development. Cell 107, 763-775.
10. Chen, L.-M., Kuo, C.-H., Lai, T.-Y., Lin, Y.-M., Su, C.-C., Hsu, H.-H., Tsai, F.-J., Tsai, C.-H., Huang, C.-Y. and Tang, C.-H. (2010). RANKL increases migration of human lung cancer cells through intercellular adhesion molecule-1 up-regulation. J. Cell. Biochem. 112, 933-941.
11. Cheng, J. Q., Lindsley, C. W., Cheng, G. Z., Yang, H. and Nicosia, S. V. (2005). The Akt/PKB pathway: molecular target for cancer drug discovery. Oncogene 24, 7482-s7492.
12. Darnay, B. G., Ni, J., Moore, P. A. and Aggarwal, B. B. (1999). Activation of NFkappaB by RANK requires tumor necrosis factor receptor-associated factor (TRAF) 6 and NF-kappaB-inducing kinase. Identification of a novel TRAF6 interaction motif. J. Biol. Chem. 274, 7724-7731.
13. David, G., Van der Schueren, B. and Bernfield, M. (1981). Basal lamina formation by normal and transformed mouse mammary epithelial cells duplicated in vitro. J. Natl. Cancer Inst. 67, 719-728.
14. Dougall, W. C. (2007). RANKL signaling in bone physiology and cancer. Curr. Opin. Support. Palliat. Care 1, 317-322.
15. Dougall, W. C., Glaccum, M., Charrier, K., Rohrbach, K., Brasel, K., De Smedt, T., Daro, E., Smith, J., Tometsko, M. E., Maliszewski, C. R. et al. (1999). RANK is essential for osteoclast and lymph node development. Genes Dev. 13, 2412-2424.
16. Duheron, V., Hess, E., Duval, M., Decossas, M., Castaneda, B., Klöpper, J. E., Amoasii, L., Barbaroux, J.-B., Williams, I. R., Yagita, H. et al. (2011). Receptor activator of NF-kappaB (RANK) stimulates the proliferation of epithelial cells of the epidermo-pilosebaceous unit. Proc. Natl. Acad. Sci. USA 108, 5342-5347.
17. Fata, J. E., Kong, Y. Y., Li, J., Sasaki, T., Irie-Sasaki, J., Moorehead, R. A., Elliott, R., Scully, S., Voura, E. B., Lacey, D. L. et al. (2000). The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development. Cell 103, 41-50.
18. Feeley, B. T., Liu, N. Q., Conduah, A. H., Krenek, L., Roth, K., Dougall, W. C., Huard, J., Dubinett, S. and Lieberman, J. R. (2006). Mixed metastatic lung cancer lesions in bone are inhibited by noggin overexpression and Rank:Fc administration. J. Bone Miner. Res. 21, 1571-1580.
19. Fernandez-Valdivia, R., Mukherjee, A., Ying, Y., Li, J., Paquet, M., Demayo, F. J. and Lydon, J. P. (2009). The RANKL signaling axis is sufficient to elicit ductal side-branching and alveologenesis in the mammary gland of the virgin mouse. Dev. Biol. 328, 127-139.
20. Gonzalez-Suarez, E., Branstetter, D., Armstrong, A., Dinh, H., Blumberg, H. and Dougall, W. C. (2007). RANK overexpression in transgenic mice with mouse mammary tumor virus promoter-controlled RANK increases proliferation and impairs alveolar differentiation in the mammary epithelia and disrupts lumen formation in cultured epithelial acini. Mol. Cell. Biol. 27, 1442-1454.
21. Gonzalez-Suarez, E., Jacob, A. P., Jones, J., Miller, R., Roudier-Meyer, M. P., Erwert, R., Pinkas, J., Branstetter, D. and Dougall, W. C. (2010). RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis. Nature 468, 103-107.
22. Hsu, C.-J., Lin, T.-Y., Kuo, C.-C., Tsai, C.-H., Lin, M.-Z., Hsu, H.-C., Fong, Y.-C. and Tang, C.-H. (2010). Involvement of integrin up-regulation in RANKL/RANK pathway of chondrosarcomas migration. J. Cell. Biochem. 111, 138-147.
23. Jones, D. H., Nakashima, T., Sanchez, O. H., Kozieradzki, I., Komarova, S. V., Sarosi, I., Morony, S., Rubin, E., Sarao, R., Hojilla, C. V. et al. (2006). Regulation of cancer cell migration and bone metastasis by RANKL. Nature 440, 692-696.
24. Joshi, P. A., Jackson, H. W., Beristain, A. G., Di Grappa, M. A., Mote, P., Clarke, C., Stingl, J., Waterhouse, P. D. and Khokha, R. (2010). Progesterone induces adult mammary stem cell expansion. Nature 465, 803-807.
25. Kim, D., Kim, S., Koh, H., Yoon, S. O., Chung, A. S., Cho, K. S. and Chung, J. (2001). Akt/PKB promotes cancer cell invasion via increased motility and metalloproteinase production. FASEB J. 15, 1953-1962.
26. Kim, N. S., Kim, H. J., Koo, B. K., Kwon, M. C., Kim, Y. W., Cho, Y., Yokota, Y., Penninger, J. M. and Kong, Y. Y. (2006). Receptor activator of NF-kappaB ligand regulates the proliferation of mammary epithelial cells via Id2. Mol. Cell. Biol. 26, 1002-1013.
27. Kitazawa, S. and Kitazawa, R. (2002). RANK ligand is a prerequisite for cancerassociated osteolytic lesions. J. Pathol. 198, 228-236.
28. Kobayashi, N., Kadono, Y., Naito, A., Matsumoto, K., Yamamoto, T., Tanaka, S. and Inoue, J. (2001). Segregation of TRAF6-mediated signaling pathways clarifies its role in osteoclastogenesis. EMBO J. 20, 1271-1280.
29. Kong, Y. Y., Yoshida, H., Sarosi, I., Tan, H. L., Timms, E., Capparelli, C., Morony, S., Oliveira-dos-Santos, A. J., Van, G., Itie, A. et al. (1999). OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397, 315-323.
30. Kotake, S., Udagawa, N., Hakoda, M., Mogi, M., Yano, K., Tsuda, E., Takahashi, K., Furuya, T., Ishiyama, S., Kim, K. J. et al. (2001). Activated human T cells directly induce osteoclastogenesis from human monocytes: possible role of T cells in bone destruction in rheumatoid arthritis patients. Arthritis Rheum. 44, 1003-1012.
31. Lacey, D. L., Timms, E., Tan, H. L., Kelley, M. J., Dunstan, C. R., Burgess, T., Elliott, R., Colombero, A., Elliott, G., Scully, S. et al. (1998). Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93, 165-176.
32. Lamothe, B., Webster, W. K., Gopinathan, A., Besse, A., Campos, A. D. and Darnay, B. G. (2007). TRAF6 ubiquitin ligase is essential for RANKL signaling and osteoclast differentiation. Biochem. Biophys. Res. Commun. 359, 1044-1049.
33. Lamoureux, F., Richard, P., Wittrant, Y., Battaglia, S., Pilet, P., Trichet, V., Blanchard, F., Gouin, F., Pitard, B., Heymann, D. et al. (2007). Therapeutic relevance of osteoprotegerin gene therapy in osteosarcoma: blockade of the vicious cycle between tumor cell proliferation and bone resorption. Cancer Res. 67, 7308-7318.
34. Lee, H. W., Park, H. K., Na, Y. J., Kim, C. D., Lee, J. H., Kim, B. S., Kim, J. B., Lee, C. W., Moon, J. O. and Yoon, S. (2008). RANKL stimulates proliferation, adhesion and IL-7 expression of thymic epithelial cells. Exp. Mol. Med. 40, 59-70.
35. Lee, J. A., Jung, J. S., Kim, D. H., Lim, J. S., Kim, M. S., Kong, C. B., Song, W. S., Cho, W. H., Jeon, D. G., Lee, S. Y. et al. (2011). RANKL expression is related to treatment outcome of patients with localized, high-grade osteosarcoma. Pediatr. Blood Cancer 56, 738-743.
36. Leibbrandt, A. and Penninger, J. M. (2008). RANK/RANKL: regulators of immune responses and bone physiology. Ann. N. Y. Acad. Sci. 1143, 123-150.
37. Lum, L., Wong, B. R., Josien, R., Becherer, J. D., Erdjument-Bromage, H., Schlöndorff, J., Tempst, P., Choi, Y. and Blobel, C. P. (1999). Evidence for a role of a tumor necrosis factor-alpha (TNF-alpha)-converting enzyme-like protease in shedding of TRANCE, a TNF family member involved in osteoclastogenesis and dendritic cell survival. J. Biol. Chem. 274, 13613-13618.
38. Meloche, S. and Pouysségur, J. (2007). The ERK1/2 mitogen-activated protein kinase pathway as a master regulator of the G1- to S-phase transition. Oncogene 26, 3227-3239.
39. Miller, R. E., Roudier, M., Jones, J., Armstrong, A., Canon, J. and Dougall, W. C. (2008). RANK ligand inhibition plus docetaxel improves survival and reduces tumor burden in a murine model of prostate cancer bone metastasis. Mol. Cancer Ther. 7, 2160-2169.
40. Molyneux, S. D., Di Grappa, M. A., Beristain, A. G., McKee, T. D., Wai, D. H., Paderova, J., Kashyap, M., Hu, P., Maiuri, T., Narala, S. R. et al. (2010). Prkar1a is an osteosarcoma tumor suppressor that defines a molecular subclass in mice. J. Clin. Invest. 120, 310-3325.
41. Mori, K., Le Goff, B., Berreur, M., Riet, A., Moreau, A., Blanchard, F., Chevalier, C., Guisle-Marsollier, I., Léger, J., Guicheux, J. et al. (2007). Human osteosarcoma cells express functional receptor activator of nuclear factor-kappa B. J. Pathol. 211, 555-562.
42. Morony, S., Capparelli, C., Sarosi, I., Lacey, D. L., Dunstan, C. R. and Kostenuik, P. J. (2001). Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis. Cancer Res. 61, 4432-4436.
43. Nakano, K., Okada, Y., Saito, K. and Tanaka, Y. (2004). Induction of RANKL expression and osteoclast maturation by the binding of fibroblast growth factor 2 to heparan sulfate proteoglycan on rheumatoid synovial fibroblasts. Arthritis Rheum. 50, 2450-2458.
44. Sabbota, A. L., Kim, H.-R. C., Zhe, X., Fridman, R., Bonfil, R. D. and Cher, M. L. (2010). Shedding of RANKL by tumor-associated MT1-MMP activates Srcdependent prostate cancer cell migration. Cancer Res. 70, 5558-5566.
45. Santini, D., Schiavon, G., Vincenzi, B., Gaeta, L., Pantano, F., Russo, A., Ortega, C., Porta, C., Galluzzo, S., Armento, G. et al. (2011). Receptor Activator of NF-kB (RANK) Expression in Primary Tumors Associates with Bone Metastasis Occurrence in Breast Cancer Patients. PLoS ONE 6, e19234.
46. Schäfer, B., Gschwind, A. and Ullrich, A. (2004). Multiple G-protein-coupled receptor signals converge on the epidermal growth factor receptor to promote migration and invasion. Oncogene 23, 991-999.
47. Scheid, M. P. and Woodgett, J. R. (2003). Unravelling the activation mechanisms of protein kinase B/Akt. FEBS Lett. 546, 108-112.
48. Schramek, D., Leibbrandt, A., Sigl, V., Kenner, L., Pospisilik, J. A., Lee, H. J., Hanada, R., Joshi, P. A., Aliprantis, A., Glimcher, L. et al. (2010). Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature 468, 98-102.
49. Soriano, J. V., Pepper, M. S., Nakamura, T., Orci, L. and Montesano, R. (1995). Hepatocyte growth factor stimulates extensive development of branching duct-like structures by cloned mammary gland epithelial cells. J. Cell Sci. 108, 413-430.
50. Tan, W., Zhang, W., Strasner, A., Grivennikov, S., Cheng, J. Q., Hoffman, R. M. and Karin, M. (2011). Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling. Nature 470, 548-553.
51. Walsh, M. C. and Choi, Y. (2003). Biology of the TRANCE axis. Cytokine Growth Factor Rev. 14, 251-263.
52. Westhoff, M.-A. and Fulda, S. (2009). Adhesion-mediated apoptosis resistance in cancer. Drug Resist. Updat. 12, 27-136.
53. Wittrant, Y., Lamoureux, F., Mori, K., Riet, A., Kamijo, A., Heymann, D. and Redini, F. (2006). RANKL directly induces bone morphogenetic protein-2 expression in RANK-expressing POS-1 osteosarcoma cells. Int. J. Oncol. 28, 261-269.
54. Wong, B. R., Rho, J., Arron, J., Robinson, E., Orlinick, J., Chao, M., Kalachikov, S., Cayani, E., Bartlett, F. S., Frankel, W. N. et al. (1997). TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells. J. Biol. Chem. 272, 25190-25194.
55. Wong, B. R., Josien, R., Lee, S. Y., Vologodskaia, M., Steinman, R. M. and Choi, Y. (1998). The TRAF family of signal transducers mediates NF-kappaB activation by the TRANCE receptor. J. Biol. Chem. 273, 28355-28359.
56. Wong, B. R., Besser, D., Kim, N., Arron, J. R., Vologodskaia, M., Hanafusa, H. and Choi, Y. (1999). TRANCE, a TNF family member, activates Akt/PKB through a signaling complex involving TRAF6 and c-Src. Mol. Cell 4,1041-1049.
57. Xing, L., Venegas, A. M., Chen, A., Garrett-Beal, L., Boyce, B. F., Varmus, H. E. and Schwartzberg, P. L. (2001). Genetic evidence for a role for Src family kinases in TNF family receptor signaling and cell survival. Genes Dev. 15, 241-253.